GO:0070780 dihydrosphingosine-1-phosphate phosphatase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070780 defines dihydrosphingosine-1-phosphate phosphatase activity, the enzyme that dephosphorylates dihydrosphingosine 1-phosphate to dihydrosphingosine and inorganic phosphate.
• This activity is conserved from yeast to humans and is carried out by integral membrane proteins such as Lcb3p in yeast and hSPP2 in humans [1, 4].
• The reaction is part of sphingolipid metabolism and helps balance the levels of bioactive sphingoid base 1-phosphates, which influence cell growth, survival, and differentiation [2, 5].
• Dihydrosphingosine 1-phosphate and sphingosine 1-phosphate can have opposing effects on signaling pathways such as TGF-beta/Smad, partly through PTEN/PPM1A-dependent mechanisms.
• Altered sphingolipid metabolism, including dihydrosphingosine 1-phosphate phosphatase activity, has been linked to human diseases such as urothelial urinary bladder cancer and metabolic liver disease [3, 6].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of genes encoding this activity in health and disease [1, 4].
Description
Dihydrosphingosine-1-phosphate phosphatase activity (GO:0070780) is a molecular function that catalyzes the hydrolysis of dihydrosphingosine 1-phosphate (also called sphinganine 1-phosphate) to dihydrosphingosine and phosphate. This reaction is a key step in sphingolipid metabolism, a pathway that produces structural membrane components and bioactive signaling lipids. The enzyme responsible for this activity belongs to the family of sphingoid long-chain base-1-phosphate phosphatases, which are integral membrane proteins. In yeast, the prototype enzyme Lcb3p has been characterized in detail, and its transmembrane topology has been determined. In humans, a related enzyme, hSPP2, was identified as a sphingosine-1-phosphate phosphohydrolase, and it also exhibits activity toward dihydrosphingosine 1-phosphate. The balance between phosphorylated and non-phosphorylated sphingoid bases is critical for cellular signaling, and the phosphatase activity of GO:0070780 directly influences this balance [2, 5]. Researchers study dihydrosphingosine-1-phosphate phosphatase activity because it modulates the levels of bioactive lipids that regulate cell growth, survival, migration, and differentiation. For example, dihydrosphingosine 1-phosphate and sphingosine 1-phosphate have opposite effects on transforming growth factor-beta (TGF-beta)/Smad signaling, and these effects are mediated through the PTEN/PPM1A-dependent pathway. This suggests that the phosphatase activity can influence major signaling cascades involved in cancer and fibrosis. Moreover, dysregulation of sphingolipid metabolism has been observed in various diseases, including urothelial urinary bladder cancer, where stage-dependent aberrations in bioactive sphingolipids occur. Therefore, understanding GO:0070780 is important for both basic cell biology and translational research. Methodologically, the activity can be assayed using radiolabeled substrates or high-performance liquid chromatography (HPLC) to quantify sphingoid base 1-phosphates [5, 7]. Yeast genetics has been instrumental in defining the enzymes and their cellular localization. More recently, CRISPR-Cas9 genome editing has enabled precise manipulation of the genes encoding these enzymes in human cells and animal models, allowing researchers to test causal relationships between the activity and disease phenotypes [1, 4]. This article provides a comprehensive overview of GO:0070780, covering its definition, mechanism, key genes, regulation, disease relevance, and research methods, with a focus on CRISPR-based approaches.
dihydrosphingosine-1-phosphate phosphatase activity At A Glance
| GO ID | GO:0070780 |
|---|---|
| GO term | dihydrosphingosine-1-phosphate phosphatase activity |
| Ontology | molecular_function |
| Synonym | dihydrosphingosine-1-phosphate phosphohydrolase activity; sphinganine-1-phosphate phosphatase activity |
| Major function | Catalysis of the dephosphorylation of dihydrosphingosine 1-phosphate to dihydrosphingosine and phosphate |
| Reaction | dihydrosphingosine 1-phosphate + H2O = dihydrosphingosine + phosphate |
| Substrate | Dihydrosphingosine 1-phosphate (sphinganine 1-phosphate) |
| Product | Dihydrosphingosine (sphinganine) and phosphate |
| Cellular location | Integral membrane protein, likely endoplasmic reticulum and other membranes |
| Representative enzymes | Yeast Lcb3p; human hSPP2 [1, 4] |
What Is GO:0070780?
Dihydrosphingosine-1-phosphate phosphatase activity (GO:0070780) is defined as the catalysis of the reaction: dihydrosphingosine 1-phosphate + H2O = dihydrosphingosine + phosphate. In other words, it is an enzyme activity that removes a phosphate group from dihydrosphingosine 1-phosphate (sphinganine 1-phosphate), producing dihydrosphingosine (sphinganine) and free phosphate. This activity is also known as dihydrosphingosine-1-phosphate phosphohydrolase activity or sphinganine-1-phosphate phosphatase activity. It belongs to the molecular function ontology and is part of sphingolipid metabolic processes.
Why Is dihydrosphingosine-1-phosphate phosphatase activity Important in Cell Biology?
Dihydrosphingosine-1-phosphate phosphatase activity is important because it regulates the cellular levels of dihydrosphingosine 1-phosphate, a bioactive sphingolipid that influences cell growth, survival, and differentiation. By removing the phosphate group, the enzyme converts a signaling lipid into a non-phosphorylated form that can be further metabolized into complex sphingolipids. This activity therefore sits at a critical branch point in sphingolipid metabolism. Dysregulation of this activity can alter the balance between dihydrosphingosine 1-phosphate and sphingosine 1-phosphate, which have been shown to have opposing effects on TGF-beta/Smad signaling through PTEN/PPM1A-dependent pathways. Such imbalances have been implicated in cancer, including urothelial urinary bladder cancer, where stage-dependent aberrations in bioactive sphingolipids are observed. Additionally, sphingolipid metabolism is linked to metabolic diseases such as fatty liver, where interventions like Lactobacillus rhamnosus GG require fibroblast growth factor 21 to exert therapeutic effects. Thus, understanding GO:0070780 is relevant for both fundamental cell biology and disease-oriented research.
• Regulates the balance of bioactive sphingoid base 1-phosphates, which control cell fate decisions.
• Modulates TGF-beta/Smad signaling, a pathway central to cancer and fibrosis.
• Influences sphingolipid metabolism, affecting membrane composition and lipid signaling.
• Its dysregulation is associated with urothelial urinary bladder cancer progression.
• May contribute to metabolic liver disease, as sphingolipid metabolism intersects with FGF21 signaling.
• Provides a potential therapeutic target for diseases driven by aberrant sphingolipid signaling [2, 3].
• Enables researchers to study lipid phosphatase mechanisms using yeast and human cell models [1, 4].
• Can be assayed with HPLC and radiolabeled substrates, facilitating drug discovery [5, 7].
• CRISPR-based editing allows precise functional interrogation of genes encoding this activity [1, 4].
• Its evolutionary conservation from yeast to humans underscores its fundamental biological importance [1, 4].
What Happens During dihydrosphingosine-1-phosphate phosphatase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs dihydrosphingosine 1-phosphate and holds it in place.
The first step in the reaction is the specific binding of the substrate, dihydrosphingosine 1-phosphate, to the active site of the phosphatase. This enzyme belongs to the family of sphingoid long-chain base-1-phosphate phosphatases, which are integral membrane proteins with a defined transmembrane topology. The substrate is a long-chain base with a phosphate group, and the enzyme must distinguish it from other phosphorylated lipids. In yeast, Lcb3p has been shown to localize to membranes and to exhibit phosphatase activity toward dihydrosphingosine 1-phosphate. The binding likely involves conserved residues in the catalytic domain, although the exact structural details remain to be fully elucidated.
Catalytic dephosphorylation
In simple terms: The enzyme cuts off the phosphate group using water.
Once bound, the enzyme catalyzes the hydrolysis of the phosphate ester bond, releasing inorganic phosphate and dihydrosphingosine. This reaction is a typical phosphatase reaction that requires water. The catalytic mechanism probably involves a nucleophilic attack by water or a hydroxide ion, often assisted by metal ions or conserved amino acid residues. The reaction is: dihydrosphingosine 1-phosphate + H2O = dihydrosphingosine + phosphate. The activity can be measured in vitro using radiolabeled substrates or by HPLC-based assays that quantify the disappearance of the substrate or the appearance of the product [5, 7].
Product release and cellular fate
In simple terms: The products are released and can be used or further processed by the cell.
After catalysis, dihydrosphingosine and phosphate are released from the enzyme. Dihydrosphingosine can then be used as a precursor for the synthesis of complex sphingolipids, such as ceramides and sphingomyelins, or it can be further phosphorylated back to dihydrosphingosine 1-phosphate by sphingosine kinases. The balance between phosphorylated and non-phosphorylated forms is crucial for cellular signaling. For example, dihydrosphingosine 1-phosphate and sphingosine 1-phosphate have opposite effects on TGF-beta/Smad signaling, and these effects are mediated through the PTEN/PPM1A-dependent pathway. Thus, the phosphatase activity directly influences the levels of these bioactive lipids and downstream signaling events.
Regulation of enzyme expression and activity
In simple terms: The cell controls how much enzyme is made and how active it is.
The expression and activity of dihydrosphingosine-1-phosphate phosphatases are regulated at multiple levels. In yeast, the expression of LCB3 is regulated in response to growth conditions and sphingolipid levels. In mammals, the activity of hSPP2 and related enzymes may be controlled by transcription factors, post-translational modifications, and interaction with other proteins. For instance, the PTEN/PPM1A-dependent pathway can influence the effects of dihydrosphingosine 1-phosphate on TGF-beta/Smad signaling, suggesting cross-talk between phosphatase activity and other signaling modules. Additionally, metabolic cues such as fructose consumption can alter sphingolipid metabolism in the liver, and fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice. These findings indicate that the activity is integrated into broader metabolic and signaling networks.
Key Genes Involved in GO:0070780 dihydrosphingosine-1-phosphate phosphatase activity
The following genes and proteins are directly or indirectly involved in dihydrosphingosine-1-phosphate phosphatase activity and related sphingolipid metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LCB3 (yeast) | Encodes a sphingoid long-chain base-1-phosphate phosphatase; prototype for GO:0070780 | Used to study enzyme topology, localization, and function in yeast [1, 5] |
| SPP2 (human) | Encodes hSPP2, a sphingosine-1-phosphate phosphohydrolase with activity toward dihydrosphingosine 1-phosphate | Human model for lipid phosphatase function and signaling |
| SGPP1 | Sphingosine-1-phosphate phosphatase 1; may dephosphorylate dihydrosphingosine 1-phosphate | Potential target for cancer and metabolic studies |
| SGPP2 | Sphingosine-1-phosphate phosphatase 2; related to hSPP2 | Implicated in sphingolipid signaling and disease |
| SPHK1 | Sphingosine kinase 1; phosphorylates sphingosine and dihydrosphingosine to their 1-phosphates | Opposes phosphatase activity; regulates bioactive lipid balance |
| SPHK2 | Sphingosine kinase 2; produces sphingosine 1-phosphate and dihydrosphingosine 1-phosphate | Influences signaling and cell fate |
| SGPL1 | Sphingosine-1-phosphate lyase 1; degrades sphingosine 1-phosphate | Affects sphingolipid metabolism and disease |
| CERS2 | Ceramide synthase 2; uses dihydrosphingosine as substrate | Links phosphatase activity to complex sphingolipid synthesis |
| CERS4 | Ceramide synthase 4; involved in sphingolipid synthesis | Potential modifier of dihydrosphingosine levels |
| DEGS1 | Dihydroceramide desaturase 1; converts dihydroceramide to ceramide | Connects dihydrosphingosine metabolism to ceramide pathways |
| PTEN | Phosphatase and tensin homolog; mediates effects of dihydrosphingosine 1-phosphate on TGF-beta/Smad signaling | Key tumor suppressor and signaling node |
| PPM1A | Protein phosphatase 1A; involved in PTEN-dependent signaling | Modulates TGF-beta/Smad pathway |
| FGF21 | Fibroblast growth factor 21; required for therapeutic effects of L. rhamnosus GG against fatty liver | Links sphingolipid metabolism to metabolic disease |
| TGFB1 | Transforming growth factor beta 1; signaling pathway affected by sphingoid base 1-phosphates | Central to fibrosis and cancer |
| SMAD2/3 | Downstream effectors of TGF-beta signaling | Readouts for sphingolipid-mediated signaling |
| MYD88 | Myeloid differentiation primary response 88; associated with autophagy and myeloid-derived suppressor cells | Context-dependent role in cancer immunology |
| LC3B (MAP1LC3B) | Autophagy marker; associated with myeloid-derived suppressor cell accumulation | Used to study autophagy in cancer |
| BECN1 | Beclin 1; autophagy regulator | Potential link between sphingolipids and autophagy |
How Is dihydrosphingosine-1-phosphate phosphatase activity Regulated?
The activity of dihydrosphingosine-1-phosphate phosphatase is regulated at multiple levels. In yeast, LCB3 expression is induced by conditions that affect sphingolipid metabolism, and the enzyme is localized to membranes [1, 5]. In mammals, the activity can be influenced by signaling pathways such as the PTEN/PPM1A-dependent pathway, which mediates the opposing effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on TGF-beta/Smad signaling. Additionally, metabolic factors such as fibroblast growth factor 21 (FGF21) are required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice, indicating that systemic metabolic cues can impact sphingolipid metabolism. Autophagy has also been positively associated with the accumulation of myeloid-derived suppressor cells in oral cancer, suggesting a link between cellular stress responses and sphingolipid signaling. However, the precise molecular mechanisms linking these pathways to dihydrosphingosine-1-phosphate phosphatase activity remain to be fully defined.
dihydrosphingosine-1-phosphate phosphatase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPP2 | Sphingolipid signaling in cancer | Knockout or overexpression in human cancer cell lines |
| LCB3 | Sphingolipid metabolism in yeast | Yeast deletion mutants and GFP tagging [1, 5] |
| PTEN | TGF-beta/Smad signaling in cancer and fibrosis | PTEN knockout or point mutation in mammalian cells |
| FGF21 | Fructose-induced fatty liver | FGF21 knockout mice treated with probiotics |
| MAP1LC3B | Autophagy in oral cancer | LC3B reporter mice or knockout cell lines |
Urothelial urinary bladder cancer
Urothelial urinary bladder cancer is characterized by stage-dependent aberrations in the metabolism of bioactive sphingolipids. This includes changes in the levels of sphingoid base 1-phosphates, which are substrates or products of dihydrosphingosine-1-phosphate phosphatase activity. The enzyme may therefore influence tumor progression by altering the balance of growth-promoting and growth-inhibitory lipids. Further studies are needed to determine whether modulating GO:0070780 activity could have therapeutic benefit in bladder cancer.
Metabolic liver disease
Sphingolipid metabolism is linked to metabolic liver disease. In a mouse model of fructose-induced fatty liver, the therapeutic effects of Lactobacillus rhamnosus GG required fibroblast growth factor 21 (FGF21). Although dihydrosphingosine-1-phosphate phosphatase activity was not directly measured in that study, the findings suggest that sphingolipid pathways, including those involving dihydrosphingosine 1-phosphate, may contribute to the pathogenesis of fatty liver and could be targeted by probiotics or FGF21-based therapies.
Cancer and autophagy
Autophagy is positively associated with the accumulation of myeloid-derived suppressor cells in 4-nitroquinoline-1-oxide-induced oral cancer. Sphingolipids, including dihydrosphingosine 1-phosphate, can influence autophagy and immune cell function. Therefore, dihydrosphingosine-1-phosphate phosphatase activity might indirectly affect tumor immunity by modulating lipid signals that regulate autophagy. However, direct evidence linking GO:0070780 to autophagy in cancer is currently limited.
TGF-beta/Smad signaling in fibrosis and cancer
Dihydrosphingosine 1-phosphate and sphingosine 1-phosphate have opposite effects on TGF-beta/Smad signaling, mediated through the PTEN/PPM1A-dependent pathway. This signaling axis is central to fibrosis and cancer progression. By controlling the levels of dihydrosphingosine 1-phosphate, the phosphatase activity of GO:0070780 can indirectly modulate TGF-beta responses. Targeting this activity might therefore alter fibrotic and oncogenic signaling, although further research is needed to validate this hypothesis in relevant disease models.
From dihydrosphingosine-1-phosphate phosphatase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of dihydrosphingosine-1-phosphate phosphatase activity alter sphingolipid levels? | CRISPR knockout of SPP2 or LCB3 in cell lines [1, 4] |
| What is the subcellular localization of the enzyme? | Knock-in of GFP or FLAG tag at the endogenous locus |
| Does a specific point mutation abolish catalytic activity? | CRISPR point mutation of catalytic residues |
| Can overexpression of the enzyme reduce dihydrosphingosine 1-phosphate signaling? | CRISPR-mediated overexpression or cDNA transfection |
| Does the enzyme regulate TGF-beta/Smad signaling? | Knockout or overexpression in combination with TGF-beta treatment and Smad reporters |
| Is the enzyme required for FGF21-mediated effects in fatty liver? | Liver-specific knockout in mice fed a fructose diet |
How to Study the dihydrosphingosine-1-phosphate phosphatase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled substrate assay | Phosphatase activity | In vitro enzyme kinetics |
| HPLC | Sphingosine-1-phosphate and dihydrosphingosine-1-phosphate levels | Quantification in biological samples |
| Mass spectrometry lipidomics | Sphingolipid profile | Global changes in sphingolipid metabolism |
| Western blot | Protein expression and phosphorylation | Signaling pathway analysis |
| GFP tagging and fluorescence microscopy | Subcellular localization | Enzyme topology and trafficking |
| CRISPR-Cas9 knockout | Loss-of-function phenotypes | Gene function studies [1, 4] |
| CRISPR knock-in | Tagged or mutant protein expression | Localization and interaction studies |
| Autophagy flux assay | Autophagic activity | Cancer and stress response studies |
Enzymatic assays for phosphatase activity
Dihydrosphingosine-1-phosphate phosphatase activity can be measured using radiolabeled substrates or by high-performance liquid chromatography (HPLC). In a typical assay, cell lysates or purified enzyme preparations are incubated with dihydrosphingosine 1-phosphate, and the release of phosphate or the formation of dihydrosphingosine is quantified. An improved HPLC method for determining sphingosine-1-phosphate in complex biological materials has been described. Yeast-based assays for sphingosine-1-phosphate phosphatases, including expression, deletion, purification, and GFP tagging, provide a robust framework for studying this activity.
Genetic manipulation in yeast and mammalian cells
Yeast genetics has been instrumental in identifying and characterizing sphingoid long-chain base-1-phosphate phosphatases. Deletion of LCB3 in yeast leads to altered sphingolipid metabolism and provides a model for studying the enzyme's function. In mammalian cells, CRISPR-Cas9 can be used to knock out SPP2 or related genes, enabling loss-of-function studies. Overexpression of wild-type or mutant enzymes can be achieved by lentiviral transduction or CRISPR-mediated knock-in of inducible cassettes [1, 4].
Lipidomics and signaling readouts
Mass spectrometry-based lipidomics allows comprehensive profiling of sphingolipids, including dihydrosphingosine 1-phosphate and sphingosine 1-phosphate, in cells and tissues. Such analyses can reveal how changes in phosphatase activity affect the broader sphingolipid network. Downstream signaling can be monitored by immunoblotting for phospho-Smad2/3, PTEN, and PPM1A. Autophagy can be assessed by LC3B immunoblotting or fluorescence microscopy.
Animal models and disease relevance
Mouse models with tissue-specific knockout or knock-in of genes encoding dihydrosphingosine-1-phosphate phosphatase activity can be used to study disease phenotypes. For example, FGF21 knockout mice have been used to demonstrate the requirement for FGF21 in the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver. Similar approaches could be applied to study the role of SPP2 in cancer and metabolic disorders. Urothelial urinary bladder cancer samples can be analyzed for stage-dependent sphingolipid aberrations.
How CRISPR Can Be Used to Study GO:0070780 dihydrosphingosine-1-phosphate phosphatase activity
Knockout
CRISPR-Cas9 knockout of genes encoding dihydrosphingosine-1-phosphate phosphatase activity, such as SPP2 in human cells or LCB3 in yeast, can be used to eliminate enzyme function. This approach reveals the consequences of loss of activity on sphingolipid levels, cell growth, and signaling pathways. For example, knockout of LCB3 in yeast alters sphingolipid metabolism and provides a model for studying the enzyme's role [1, 5]. In mammalian cells, SPP2 knockout can be combined with lipidomics and phospho-Smad2/3 immunoblotting to assess downstream effects.
Point Mutation
CRISPR-mediated point mutation can be used to introduce catalytically inactivating mutations in the active site of the phosphatase. This allows researchers to distinguish between the enzymatic activity and any structural or scaffolding functions of the protein. For instance, mutating conserved residues in Lcb3p or hSPP2 can abolish phosphatase activity while preserving protein expression and localization [1, 4]. Such mutants are valuable for dissecting the specific contribution of the catalytic activity to cellular phenotypes.
Knock-in
Knock-in of epitope tags (e.g., GFP, FLAG) or fluorescent proteins at the endogenous locus enables real-time visualization and biochemical purification of the enzyme. This approach has been used to determine the transmembrane topology and cellular localization of Lcb3p in yeast. In human cells, knock-in of tags into SPP2 can facilitate interaction studies and live-cell imaging. Additionally, knock-in of inducible promoters can provide controlled expression for dose-response experiments.
Overexpression
CRISPR-mediated overexpression, for example by knocking in a strong promoter or using CRISPR activation (CRISPRa), can increase the levels of dihydrosphingosine-1-phosphate phosphatase. Overexpression studies can test whether excess enzyme activity reduces dihydrosphingosine 1-phosphate levels and alters signaling. For example, overexpression of hSPP2 or related phosphatases can suppress TGF-beta/Smad signaling in a PTEN/PPM1A-dependent manner. Such models are useful for identifying gain-of-function phenotypes and potential therapeutic effects.
How EDITGENE Supports dihydrosphingosine-1-phosphate phosphatase activity Research
Researchers studying dihydrosphingosine-1-phosphate phosphatase activity-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. CRISPR-based genome editing provides a precise way to manipulate these genes in relevant cell models, enabling loss-of-function, gain-of-function, and tagging studies. EDITGENE offers a comprehensive suite of services to support such research, from knockout cell line generation to library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for dihydrosphingosine-1-phosphate phosphatase activity research.
Frequently Asked Questions About dihydrosphingosine-1-phosphate phosphatase activity
What is dihydrosphingosine-1-phosphate phosphatase activity?
It is an enzyme activity that removes a phosphate group from dihydrosphingosine 1-phosphate, producing dihydrosphingosine and phosphate. It is classified as GO:0070780 in the Gene Ontology.
What genes are involved in dihydrosphingosine-1-phosphate phosphatase activity?
Key genes include LCB3 in yeast and SPP2 (hSPP2) in humans, as well as related genes such as SGPP1 and SGPP2 [1, 4].
What is the reaction catalyzed by GO:0070780?
The reaction is: dihydrosphingosine 1-phosphate + H2O = dihydrosphingosine + phosphate.
How is dihydrosphingosine-1-phosphate phosphatase activity measured?
It can be measured using radiolabeled substrate assays, HPLC, or mass spectrometry-based lipidomics [5, 7].
Why is dihydrosphingosine-1-phosphate phosphatase activity important in cancer?
It regulates bioactive sphingolipid levels that influence cell growth and signaling. Dysregulation has been linked to urothelial urinary bladder cancer and other cancers.
What is the difference between dihydrosphingosine 1-phosphate and sphingosine 1-phosphate?
They are related sphingoid base 1-phosphates. They can have opposing effects on signaling pathways such as TGF-beta/Smad.
How does dihydrosphingosine 1-phosphate affect TGF-beta signaling?
It can modulate TGF-beta/Smad signaling through the PTEN/PPM1A-dependent pathway, often in opposition to sphingosine 1-phosphate.
Can CRISPR be used to study dihydrosphingosine-1-phosphate phosphatase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression can be used to manipulate genes encoding this activity and study their functions [1, 4].
What diseases are associated with sphingolipid metabolism?
Diseases include urothelial urinary bladder cancer, metabolic liver disease, and conditions involving fibrosis and autophagy dysregulation [3, 6, 8].
Where can I get CRISPR cell models for sphingolipid research?
EDITGENE provides custom knockout, point mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics services for sphingolipid research.
Conclusion
Dihydrosphingosine-1-phosphate phosphatase activity (GO:0070780) is a conserved enzymatic function that regulates the balance of bioactive sphingoid base 1-phosphates. By dephosphorylating dihydrosphingosine 1-phosphate, it influences sphingolipid metabolism and signaling pathways such as TGF-beta/Smad, with implications for cancer, metabolic liver disease, and other disorders [1, 2, 3, 6]. Understanding this activity requires a combination of biochemical assays, genetic models, and lipidomics. CRISPR-based genome editing has emerged as a powerful tool to dissect the causal roles of the genes encoding this activity, enabling knockout, point mutation, knock-in, and overexpression studies in relevant cell and animal models [1, 4]. Continued research on GO:0070780 will likely uncover new therapeutic opportunities targeting sphingolipid metabolism.
References
- 1. Kihara A et al.. 2003. Transmembrane topology of sphingoid long-chain base-1-phosphate phosphatase, Lcb3p.. Genes Cells 8(6):525-35 PMID: 12786943
- 2. Bu S et al.. 2008. Opposite effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on transforming growth factor-beta/Smad signaling are mediated through the PTEN/PPM1A-dependent pathway.. J Biol Chem 283(28):19593-602 PMID: 18482992
- 3. Młynarczyk G et al.. 2024. Urothelial Urinary Bladder Cancer Is Characterized by Stage-Dependent Aberrations in Metabolism of Bioactive Sphingolipids.. Int J Mol Sci 25(22) PMID: 39595959
- 4. Ogawa C et al.. 2003. Identification and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2.. J Biol Chem 278(2):1268-72 PMID: 12411432
- 5. Mao C et al.. 2000. Yeast sphingosine-1-phosphate phosphatases: assay, expression, deletion, purification, and cellular localization by GFP tagging.. Methods Enzymol 311:223-32 PMID: 10563329
- 6. Zhao C et al.. 2019. Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.. Mol Metab 29:145-157 PMID: 31668386
- 7. Ruwisch L et al.. 2001. An improved high-performance liquid chromatographic method for the determination of sphingosine-1-phosphate in complex biological materials.. Naunyn Schmiedebergs Arch Pharmacol 363(3):358-63 PMID: 11284453
- 8. Wu JS et al.. 2018. Autophagy is positively associated with the accumulation of myeloid‑derived suppressor cells in 4‑nitroquinoline‑1‑oxide‑induced oral cancer.. Oncol Rep 40(6):3381-3391 PMID: 30272335
